Advertisement

A toll-like receptor 9 agonist sensitizes mice to mitochondrial dysfunction-induced hepatic apoptosis via the Fas/FasL pathway

  • Binbin Song
  • Shigeki Aoki
  • Cong Liu
  • Kousei ItoEmail author
Molecular Toxicology

Abstract

Early hepatocyte death occurs in most liver injury cases and triggers liver inflammation, which in combination with other risk factors leads to the development of liver disease. However, the pathogenesis of early phase hepatocyte death remains poorly understood. Here, C57BL/6J mice were treated with the hepatotoxic drug flucloxacillin (FLUX) and the toll-like receptor 9 agonist CpG oligodeoxynucleotide (ODN) to reproduce the early phase of drug-induced hepatotoxicity and investigate its pathogenesis. C57BL/6J mice were treated with FLUX (100 mg/kg, gavage) alone or in combination with ODN (40 μg/mouse, intraperitoneally). Plasma alanine aminotransferase (ALT) level was measured as a marker of hepatotoxicity. FLUX or ODN alone was insufficient to induce ALT elevation, whereas combination treatment with FLUX and ODN increased ALT levels 24 h after FLUX treatment and upregulated Fas ligand in natural killer T (NKT) cells and Fas in hepatocytes. FLUX induced mitochondrial permeability transition (MPT), and pretreatment with ODN sensitized mitochondria to FLUX-induced MPT. The increase in ALT levels induced by ODN and FLUX co-treatment was suppressed in Fas ligand (gld/gld)-deficient mice and in mice deficient in a component of MPT pore opening (cyclophilin D-knockout mice). These results suggested that ODN activated the Fas/Fas ligand-mediated pathway in NKT cells and hepatocytes, which may predispose to FLUX-induced mitochondrial dysfunction and lead to early phase hepatocyte apoptosis. Taken together, these findings elucidate a potentially novel mechanism underlying drug-induced early phase hepatocyte death related to the Fas/Fas ligand death receptor pathway and mitochondrial dysfunction.

Keywords

Flucloxacillin NKT Liver injury Innate immunity CpG-ODN 

Abbreviations

DILI

Drug-induced liver injury

FLUX

Flucloxacillin

HLA

Human leukocyte antigen

ALT

Alanine aminotransferase

AST

Aspartate transaminase

T-Bil

Total bilirubin

NKT

Natural killer T

NK

Natural killer

TLR9

Toll-like receptor 9

HMGB-1

High-mobility group box-1

ODN

CpG oligodeoxynucleotide

i.p.

Intraperitoneal injection

FasL

Fas ligand

LMNC

Liver mononuclear cell

TCR

T cell receptor

MPT

Mitochondrial permeability transition

FACS

Fluorescence-activated cell sorting

TRAIL

TNF-related apoptosis-inducing ligand

α-GalCer

α-Galactosylceramide

Cyp D

Cyclophilin D

CsA

Cyclosporin A

ROS

Reactive oxygen species

Notes

Acknowledgements

This work was supported by the Japan Society for the Promotion of Science [JSPS KAKENHI, Grant No. 15H04661 to K.I.].

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interests in association with this manuscript.

Supplementary material

204_2019_2454_MOESM1_ESM.pptx (270 kb)
Supplementary material 1 (PPTX 270 kb)

References

  1. Burban A, Sharanek A, Guguen-Guillouzo C, Guillouzo A (2018) Endoplasmic reticulum stress precedes oxidative stress in antibiotic-induced cholestasis and cytotoxicity in human hepatocytes. Free Radical Bio Med 115:166–178.  https://doi.org/10.1016/j.freeradbiomed.2017.11.017 CrossRefGoogle Scholar
  2. Cai SY, Ouyang X, Chen Y et al (2017) Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight.  https://doi.org/10.1172/jci.insight.90780 Google Scholar
  3. Daly AK, Donaldson PT, Bhatnagar P et al (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:U816–U871.  https://doi.org/10.1038/ng.379 CrossRefGoogle Scholar
  4. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516.  https://doi.org/10.1080/01926230701320337 CrossRefGoogle Scholar
  5. Fairley CK, McNeil JJ, Desmond P et al (1993) Risk factors for development of flucloxacillin associated jaundice. BMJ 306:233–235CrossRefGoogle Scholar
  6. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B (2012) Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 56:1283–1292.  https://doi.org/10.1016/j.jhep.2012.01.019 CrossRefGoogle Scholar
  7. Garcia-Martinez I, Santoro N, Chen Y et al (2016) Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 126:859–864.  https://doi.org/10.1172/jci83885 CrossRefGoogle Scholar
  8. Gong SH, Lan T, Zeng L et al (2018) Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol 69:51–59.  https://doi.org/10.1016/j.jhep.2018.02.024 CrossRefGoogle Scholar
  9. Haga S, Kanno A, Ozawa T et al (2018) Detection of necroptosis in ligand-mediated and hypoxia-induced injury of hepatocytes using a novel optic probe-detecting receptor-interacting protein (RIP)1/RIP3 binding. Oncol Res 26:503–513.  https://doi.org/10.3727/096504017x15005102445191 CrossRefGoogle Scholar
  10. Hirao T, Yamaguchi M, Kikuya M et al (2018) Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. Cancer Sci 109:121–131.  https://doi.org/10.1111/cas.13442 CrossRefGoogle Scholar
  11. Hughes CA, Foisy MM, Dewhurst N et al (2008) Abacavir hypersensitivity reaction: an update. Ann Pharmacother 42:387–396.  https://doi.org/10.1345/aph.1K522 CrossRefGoogle Scholar
  12. Klinman DM (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4:248–257.  https://doi.org/10.1038/nri1329 CrossRefGoogle Scholar
  13. Lakehal F, Dansette PM, Becquemont L et al (2001) Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 14:694–701.  https://doi.org/10.1021/tx0002435 CrossRefGoogle Scholar
  14. Li YT, Hafey MJ, Duong H et al (2017) Antibiotic-induced elevations of plasma bile acids in rats independent of Bsep inhibition. Toxicol Sci 157:30–40.  https://doi.org/10.1093/toxsci/kfx015 Google Scholar
  15. Liu C, Sekine S, Ito K (2016) Assessment of mitochondrial dysfunction-related, drug-induced hepatotoxicity in primary rat hepatocytes. Toxicol Appl Pharmacol 302:23–30.  https://doi.org/10.1016/j.taap.2016.04.010 CrossRefGoogle Scholar
  16. Ma C, Han M, Heinrich B et al (2018) Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science.  https://doi.org/10.1126/science.aan5931 Google Scholar
  17. Monshi MM, Faulkner L, Gibson A et al (2013) Human leukocyte antigen HLA-B*57:01 -restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57:727–739.  https://doi.org/10.1002/hep.26077 CrossRefGoogle Scholar
  18. Nakamoto N, Amiya T, Aoki R et al (2017) Commensal lactobacillus controls immune tolerance during acute liver injury in mice. Cell Rep 21:1215–1226.  https://doi.org/10.1016/j.celrep.2017.10.022 CrossRefGoogle Scholar
  19. Nattrass R, Faulkner L, Vocanson M et al (2015) Activation of flucloxacillin-specific CD8+ T-cells with the potential to promote hepatocyte cytotoxicity in a mouse model. Toxicol Sci 146:146–156.  https://doi.org/10.1093/toxsci/kfv077 CrossRefGoogle Scholar
  20. Olsson R, Wiholm BE, Sand C et al (1992) Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 15:154–161CrossRefGoogle Scholar
  21. Pachkoria K, Lucena M, Crespo E et al (2008) Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49:107–114.  https://doi.org/10.1016/j.jhep.2008.03.017 CrossRefGoogle Scholar
  22. Pavlos R, Mallal S, Ostrov D et al (2015) T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med 66:439–454.  https://doi.org/10.1146/annurev-med-050913-022745 CrossRefGoogle Scholar
  23. Regenthal R, Krueger M, Koeppel C, Preiss R (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monitor Comp 15:529–544.  https://doi.org/10.1023/A:1009935116877 CrossRefGoogle Scholar
  24. Robinson MW, Harmon C, O’Farrelly C (2016) Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 13:267–276.  https://doi.org/10.1038/cmi.2016.3 CrossRefGoogle Scholar
  25. Russmann S, Kaye JA, Jick SS, Jick H (2005) Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database. Brit J Clin Pharmaco 60:76–82.  https://doi.org/10.1111/j.1365-2125.2005.02370.x CrossRefGoogle Scholar
  26. Sagiv-Barfi I, Czerwinski DK, Levy S et al (2018) Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med.  https://doi.org/10.1126/scitranslmed.aan4488 Google Scholar
  27. Segawa M, Sekine S, Sato T, Ito K (2018) Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat. J Toxicol Sci 43:339–351.  https://doi.org/10.2131/jts.43.339 CrossRefGoogle Scholar
  28. Shinde R, Hezaveh K, Halaby MJ et al (2018) Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat Immunol 19:571.  https://doi.org/10.1038/s41590-018-0107-1 CrossRefGoogle Scholar
  29. Song BB, Aoki S, Liu C, Susukida T, Ito K (2018) An animal model of abacavir-induced HLA-mediated liver injury. Toxicol Sci 162:713–723.  https://doi.org/10.1093/toxsci/kfy001 CrossRefGoogle Scholar
  30. Takai S, Higuchi S, Yano A et al (2015) Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. J Appl Toxicol 35:142–151.  https://doi.org/10.1002/jat.3002 CrossRefGoogle Scholar
  31. Teratani T, Tomita K, Suzuki T et al (2017) Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling. J Hepatol 67:780–790.  https://doi.org/10.1016/j.jhep.2017.05.020 CrossRefGoogle Scholar
  32. Tohme S, Yazdani HO, Liu Y et al (2017) Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction. Hepatology 66:182–197.  https://doi.org/10.1002/hep.29184 CrossRefGoogle Scholar
  33. Wilson MT, Johansson C, Olivares-Villagómez D et al (2003) The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 100:10913–10918.  https://doi.org/10.1073/pnas.1833166100 CrossRefGoogle Scholar
  34. Yip LY, Aw CC, Lee SH et al (2018) The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology 67:282–295.  https://doi.org/10.1002/hep.29327 CrossRefGoogle Scholar
  35. Yuksel M, Wang Y, Tai N et al (2015) A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 62:1536–1550.  https://doi.org/10.1002/hep.27998 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Binbin Song
    • 1
  • Shigeki Aoki
    • 1
  • Cong Liu
    • 1
  • Kousei Ito
    • 1
    Email author
  1. 1.Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical SciencesChiba UniversityChibaJapan

Personalised recommendations